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Background:  It is unknown whether patients with a prior history of coronary revascularization respond in a similar fashion to patients without.
Methods:  3130 patients with coronary artery disease who participated in trials that monitored atheroma progression with serial intravascular 
ultrasound were stratified according to prior revascularization. Groups were compared with regard to clinical characteristics and disease burden at 
baseline and on serial assessment.
Results:  45% of patients underwent prior revascularization. Patients with a prior revascularization were more likely to be smokers (24 v 20%, 
p=0.008), have a history of dislipidemia (88 v 69%, p<0.001) and heart failure (4.6 v 2.9%, p=0.011). These patients were also more likely to 
be treated with aspirin (97 v 92%, p<0.001), statins (96 v 92%, p<0.001) and β-blockers (82 v 72%, p<0.001). Prior revascularization subjects 
demonstrated higher levels of LDL-C (106±38 v 96±32mg/dL, p<0.001), triglyceride (150 v 137mg/dL, p<0.001), apoB (104±39 v 86±32mg/
dL, p<0.001) and lower levels of HDL-C (42±11 v 43±12mg/dL, p=0.007) at baseline. On serial evaluation greater reductions in LDL-C (-18±38 
v -8.3±35mg/dL, p<0.001), triglyceride (-27 v -15mg/dL, p=0.002), apoB (-17±32 v -8.7±30mg/dL, p<0.001) and a smaller increase in HDL-C 
(2.7±11 v 6.4±15mg/dL, p<0.001) was observed. At baseline, patients with a prior revascularization had more extensive atherosclerosis with a 
greater percent atheroma volume (PAV) (40±9 v 37±9.1%, p<0.001), total atheroma volume (TAV) (195±88 v 186±80mm3, p=0.018) and more 
images containing calcium (32±25 v 28±24%, p<0.001). This was associated with constrictive remodeling of vessel (482±172 v 494±170mm3, 
p=0.03) and lumen (287±105 v 308±115mm3, p<0.001) volumes. Despite this, progression of PAV (0.6±0.2 v 0.6±0.2%, p=0.82) and TAV 
(-2.1±1.7 v -1.6±1.7mm3, p=0.55) did not differ between the two groups.
Conclusions:  While patients with a prior history of coronary revascularization harbor more extensive and calcified disease, aggressive use of anti-
atherosclerotic therapies is likely to have a beneficial impact on the natural history of atheroma progression.
